Analytical Data
-
基因名
HLA-A*03:01&B2M&KRAS G12C(VVGACGVGK) Monomer
- Application
-
别名
HLA-A*0301 & B2M & KRASG12C (VVGACGVGK)
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
NP_002107.3 (G25-T305)&P61769
-
表达区间
NP_002107.3 (G25-T305)&P61769 (I21-M119)&VVGACGVGK
-
分子量
40-46 kDa and 12 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The HLA-A*03:01 molecule, a prevalent human leukocyte antigen (HLA), plays a crucial role in the immune system by presenting peptides to T cells, thereby influencing immune recognition of pathogens and tumor cells. In the context of cancer immunotherapy, identification of tumor-specific antigens is vital. KRAS mutations, particularly KRAS G12C, are common in various cancers, contributing to oncogenesis and tumor progression. The KRAS G12C variant presents a unique peptide (VVGACGVGK) that can be recognized by HLA-A*03:01, making it a potential target for therapeutic approaches. The combination of HLA-A*03:01, beta-2-microglobulin (B2M), and the KRAS G12C derivative in a monomeric recombinant protein offers an innovative platform for studying T cell responses and developing targeted immunotherapies. By understanding the binding affinity and stability of the peptide-HLA complex, researchers aim to enhance vaccine designs and T cell engagers that can specifically activate the immune response against KRAS G12C-expressing tumors, possibly leading to improved clinical outcomes for patients with KRAS-driven malignancies. This research not only contributes to the burgeoning field of personalized cancer vaccines but also provides insights into the intricacies of HLA-peptide interactions essential for effective immune responses.
